期刊文献+

结核分枝杆菌特异性抗原Rv3117的克隆表达和诱导小鼠免疫应答的实验研究 被引量:2

Cloning,expression and immune response in mice of specific antigen Rv3117 from M. tuberculosis
下载PDF
导出
摘要 目的克隆表达结核分枝杆菌Rv3117蛋白,并进行诱导小鼠免疫应答的初步研究。方法通过聚合酶链反应(PCR)扩增结核分枝杆菌Rv3117基因,克隆入pET32a载体,构建重组质粒pET32a-Rv3117,转化入大肠埃希菌BL21(E.coli)plysS(DE3),异丙基硫代-β-D-半乳糖苷(IPTG)诱导表达,镍柱亲和纯化,通过SDS-PAGE鉴定其表达情况;以目的蛋白免疫C57BL/6小鼠血清并行Western blotting分析。结果成功构建原核表达载体pET32a-Rv3117,获得纯化的目的蛋白,其在E.coli BL21 plysS(DE3)中主要以可溶性形式表达,相对分子质量(48 100)与预期相符。Western blotting分析结果显示在目标位置有阳性条带。结论成功克隆结核分枝杆菌重组蛋白Rv3117,其能够诱导C57BL/6小鼠的免疫应答。 Objective To clone recombinant protein Rv3117 from M. tuberculosis, and investigate its immune response in mice. Methods The gene encoding Rv3117 protein was amplified by PCR from genome DNA of M. tuberculosis, and was then cloned into corresponding site of the expression vector pET-32a. The recombinant plasmid pET32a-Rv3117 was transformed into E. coli BL21 plysS (DE3), induced with isopropyl-β-D-thiogalaetopyranoside (IPTG), and purified by Ni- NTA purification system. The expression of recombinant protein was identified by SDS-PAGE analysis. Western blotting was performed on sera from Rv3117-immunlzed C57BL/6 mice. Results The prokaryotic expression vector pET32a-Rv3117 was successfully constructed. The target protein was expressed in soluble form in E. coli BL21 plysS ( DE3), with the relative molecular weight of 48 100, which was in line with the expectations. Western blotting revealed a positive stripe at the destination. Conclusion The recombinant protein Rv3117 has been successfully cloned from M. tuberculosis, which could induce immune response in mice.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2012年第11期1444-1447,共4页 Journal of Shanghai Jiao tong University:Medical Science
基金 国家自然科学基金(81271794) 上海市科委科技支撑项目(12441903300)~~
关键词 结核分枝杆菌 Rv3117 克隆 WESTERN BLOTTING M. tuberculosis Rv3117 clone Western blotting
  • 相关文献

同被引文献25

  • 1World Health Orgaoization. Global tuberculosis control[RJ. Geneva: World Health Organization, 2012.
  • 2Garg NK, Dwivedi P,Jain A, et al. Development of novel carrier ( s ) mediated tuberculosis vaccine: more than a tour de force[J] . EurJ Pharm Sci ,2014 ,62: 227 - 242.
  • 3Aagaard C, Hoang T, DietrichJ, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure[J]. Nat Med, 2011, 17(2): 189 -194.
  • 4Billeskov R, Elvang TT, Andersen PL, et al. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity[J]. PLoS One, 2012, 7(6): e39909.
  • 5PittJ M, Blankley S, McShane H, et al. Vaccination against tuber?culosis: how can we better BCG?[J] Microb Pathog, 2013, 58: 2 -16.
  • 6Lin X, Xu S, Yang Y, et al. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37 R v[J]. Protein Expr Purif, 2009, 64 (1 ) : 8 - 15.
  • 7Shaban K, Amoudy HA, Mustafa AS. Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis[J] . Clin Vaccine Immunol, 2013, 20 (8) : 1230 - 1237.
  • 8Wedlock DN, Denis M, Painter GF, et al. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone[J]. Clin Vaccine Immunol. 2008. 15(5): 765 -772.
  • 9Hu S. Chen H, MaJ. et al. CpG7909 adjuvant enhanced immuno?genicity efficacy in mice immunized with ESAT6-Ag85 A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection[J].J Appl M icrobiol, 2013, 115 (5): 1203 - 1211.
  • 10Bishai W ,Sullivan Z, Bloom BR, et al. Bettering BCG: a tough task for a TB vaccine?[J] Nat M ed, 2013, 19 ( 4 ) : 410 - 41 I .

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部